Targeting ErbB receptor signaling: a pan-ErbB approach to cancer
CD Britten - Molecular cancer therapeutics, 2004 - AACR
The ErbB receptors are localized to the cell membrane where they are activated by ligand to
trigger a network of signaling pathways. In some cancer cells, dysregulation of ErbB …
trigger a network of signaling pathways. In some cancer cells, dysregulation of ErbB …
Recent advances in novel targeted therapies for HER2-positive breast cancer
CG Murphy, PG Morris - Anti-cancer drugs, 2012 - journals.lww.com
The monoclonal antibody trastuzumab has improved the outcomes of patients with breast
cancer that overexpresses the human epidermal growth factor receptor 2 (HER2). However …
cancer that overexpresses the human epidermal growth factor receptor 2 (HER2). However …
Multimodality imaging of the HER-kinase axis in cancer
The human epidermal growth factor receptor (HER) family of receptor tyrosine kinases
controls critical pathways involved in epithelial cell differentiation, growth, division, and …
controls critical pathways involved in epithelial cell differentiation, growth, division, and …
Inhibition of Tumor-associated Fatty Acid Synthase Hyperactivity Induces Synergistic Chemosensitization of HER-2/neu-Overexpressing Human Breast Cancer Cells …
JA Menendez, R Lupu, R Colomer - Breast cancer research and treatment, 2004 - Springer
The lipogenic enzyme fatty acid synthase (FAS) is differentially overexpressed and
hyperactivated in a biologically aggressive subset of breast carcinomas and minimally in …
hyperactivated in a biologically aggressive subset of breast carcinomas and minimally in …
Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA …
K McLarty, B Cornelissen, Z Cai… - Journal of Nuclear …, 2009 - Soc Nuclear Med
Pertuzumab is a HER2 dimerization inhibitor that binds to an epitope unique from that of
trastuzumab. Our objective was to determine whether SPECT with 111In …
trastuzumab. Our objective was to determine whether SPECT with 111In …
Targeting the HER-kinase axis in cancer
The human epidermal growth factor receptor (HER) family of receptor tyrosine kinases
controls critical pathways involved in the differentiation, growth, division, and motility of …
controls critical pathways involved in the differentiation, growth, division, and motility of …
ErbB-directed immunotherapy: antibodies in current practice and promising new agents
E Friedländer, M Barok, J Szöllősi, G Vereb - Immunology letters, 2008 - Elsevier
The ErbB family is well known for its significance in oncogenesis. As bad prognostic
markers, overexpressed or mutated ErbB1 and ErbB2 have an important role in the …
markers, overexpressed or mutated ErbB1 and ErbB2 have an important role in the …
Cell‐specific biomarkers and targeted biopharmaceuticals for breast cancer treatment
M Liu, Z Li, J Yang, Y Jiang, Z Chen, Z Ali… - Cell …, 2016 - Wiley Online Library
Breast cancer is the second leading cause of cancer death among women, and its related
treatment has been attracting significant attention over the past decades. Among the various …
treatment has been attracting significant attention over the past decades. Among the various …
Cooperative antitumor activities of carnosic acid and Trastuzumab in ERBB2+ breast cancer cells
C D'Alesio, G Bellese, MC Gagliani, C Aiello… - Journal of Experimental …, 2017 - Springer
Background ERBB2 is overexpressed in up to 20–30% of human breast cancers (BCs), and
it is associated with aggressive disease. Trastuzumab (Tz), a humanized monoclonal …
it is associated with aggressive disease. Trastuzumab (Tz), a humanized monoclonal …
Mechanisms of trastuzumab resistance and their clinical implications
Trastuzumab (Herceptin™) is an excellent model of rationally designed targeted cancer
treatment. However, less than 35% of patients with ErbB2‐positive breast tumors respond to …
treatment. However, less than 35% of patients with ErbB2‐positive breast tumors respond to …